621 related articles for article (PubMed ID: 25303727)
1. Design and synthesis of benzimidazole analogs endowed with oxadiazole as selective COX-2 inhibitor.
Rathore A; Rahman MU; Siddiqui AA; Ali A; Shaharyar M
Arch Pharm (Weinheim); 2014 Dec; 347(12):923-35. PubMed ID: 25303727
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and evaluation of benzimidazole derivatives as selective COX-2 inhibitors.
Rathore A; Mujeeb-Ur-Rahman ; Siddiqui AA; Ali A; Yar MS
Med Chem; 2015; 11(2):188-99. PubMed ID: 25134430
[TBL] [Abstract][Full Text] [Related]
3. Design and synthesis of novel 2-phenyl-5-(1,3-diphenyl-1H-pyrazol-4-yl)-1,3,4-oxadiazoles as selective COX-2 inhibitors with potent anti-inflammatory activity.
Bansal S; Bala M; Suthar SK; Choudhary S; Bhattacharya S; Bhardwaj V; Singla S; Joseph A
Eur J Med Chem; 2014 Jun; 80():167-74. PubMed ID: 24780593
[TBL] [Abstract][Full Text] [Related]
4. In vivo anti-inflammatory activity and docking study of newly synthesized benzimidazole derivatives bearing oxadiazole and morpholine rings.
Rathore A; Sudhakar R; Ahsan MJ; Ali A; Subbarao N; Jadav SS; Umar S; Yar MS
Bioorg Chem; 2017 Feb; 70():107-117. PubMed ID: 27923497
[TBL] [Abstract][Full Text] [Related]
5. Benzimidazole bearing oxadiazole and triazolo-thiadiazoles nucleus: design and synthesis as anticancer agents.
Husain A; Rashid M; Mishra R; Parveen S; Shin DS; Kumar D
Bioorg Med Chem Lett; 2012 Sep; 22(17):5438-44. PubMed ID: 22840417
[TBL] [Abstract][Full Text] [Related]
6. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
7. New Coumarin Derivatives as Potent Selective COX-2 Inhibitors: Synthesis, Anti-Inflammatory, QSAR, and Molecular Modeling Studies.
Dawood DH; Batran RZ; Farghaly TA; Khedr MA; Abdulla MM
Arch Pharm (Weinheim); 2015 Dec; 348(12):875-88. PubMed ID: 26462142
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of benzimidazoles bearing oxadiazole nucleus as anticancer agents.
Rashid M; Husain A; Mishra R
Eur J Med Chem; 2012 Aug; 54():855-66. PubMed ID: 22608854
[TBL] [Abstract][Full Text] [Related]
9. Synthesis, characterization, evaluation and molecular dynamics studies of 5, 6-diphenyl-1,2,4-triazin-3(2H)-one derivatives bearing 5-substituted 1,3,4-oxadiazole as potential anti-inflammatory and analgesic agents.
Banerjee AG; Das N; Shengule SA; Srivastava RS; Shrivastava SK
Eur J Med Chem; 2015 Aug; 101():81-95. PubMed ID: 26117820
[TBL] [Abstract][Full Text] [Related]
10. New Ferrocene Compounds as Selective Cyclooxygenase (COX-2) Inhibitors: Design, Synthesis, Cytotoxicity and Enzyme-inhibitory Activity.
Farzaneh S; Zeinalzadeh E; Daraei B; Shahhosseini S; Zarghi A
Anticancer Agents Med Chem; 2018; 18(2):295-301. PubMed ID: 28971779
[TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.
Sever B; Altıntop MD; Özdemir A; Akalın Çiftçi G; Ellakwa DE; Tateishi H; Radwan MO; Ibrahim MAA; Otsuka M; Fujita M; Ciftci HI; Ali TFS
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171861
[TBL] [Abstract][Full Text] [Related]
12. New methyl 5-(halomethyl)-1-aryl-1H-1,2,4-triazole-3-carboxylates as selective COX-2 inhibitors and anti-inflammatory agents: Design, synthesis, biological evaluation, and docking study.
Li SM; Tsai SE; Chiang CY; Chung CY; Chuang TJ; Tseng CC; Jiang WP; Huang GJ; Lin CY; Yang YC; Fuh MT; Wong FF
Bioorg Chem; 2020 Nov; 104():104333. PubMed ID: 33142408
[TBL] [Abstract][Full Text] [Related]
13. Novel class of benzimidazole-thiazole hybrids: The privileged scaffolds of potent anti-inflammatory activity with dual inhibition of cyclooxygenase and 15-lipoxygenase enzymes.
Maghraby MT; Abou-Ghadir OMF; Abdel-Moty SG; Ali AY; Salem OIA
Bioorg Med Chem; 2020 Apr; 28(7):115403. PubMed ID: 32127262
[TBL] [Abstract][Full Text] [Related]
14. New benzimidazothiazole derivatives as anti-inflammatory, antitumor active agents: Synthesis, in-vitro and in-vivo screening and molecular modeling studies.
El-Kerdawy MM; Ghaly MA; Darwish SA; Abdel-Aziz HA; Elsheakh AR; Abdelrahman RS; Hassan GS
Bioorg Chem; 2019 Mar; 83():250-261. PubMed ID: 30391698
[TBL] [Abstract][Full Text] [Related]
15. Synthesis, biological evaluation and docking analysis of 3-methyl-1-phenylchromeno[4,3-c]pyrazol-4(1H)-ones as potential cyclooxygenase-2 (COX-2) inhibitors.
Grover J; Kumar V; Sobhia ME; Jachak SM
Bioorg Med Chem Lett; 2014 Oct; 24(19):4638-4642. PubMed ID: 25219899
[TBL] [Abstract][Full Text] [Related]
16. Novel acid-type cyclooxygenase-2 inhibitors: Design, synthesis, and structure-activity relationship for anti-inflammatory drug.
Hayashi S; Ueno N; Murase A; Nakagawa Y; Takada J
Eur J Med Chem; 2012 Apr; 50():179-95. PubMed ID: 22373734
[TBL] [Abstract][Full Text] [Related]
17. Synthesis and biological evaluation of pyridazinone derivatives as selective COX-2 inhibitors and potential anti-inflammatory agents.
Ahmed EM; Kassab AE; El-Malah AA; Hassan MSA
Eur J Med Chem; 2019 Jun; 171():25-37. PubMed ID: 30904755
[TBL] [Abstract][Full Text] [Related]
18. Synthesis of novel pyrazole–thiadiazole hybrid as potential potent and selective cyclooxygenase-2 (COX-2) inhibitors.
Alegaon SG; Hirpara MB; Alagawadi KR; Hullatti KK; Kashniyal K
Bioorg Med Chem Lett; 2014 Nov; 24(22):5324-9. PubMed ID: 25444084
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of substituted hydrazone and pyrazole derivatives as selective COX-2 inhibitors: Molecular docking study.
El-Sayed MA; Abdel-Aziz NI; Abdel-Aziz AA; El-Azab AS; Asiri YA; Eltahir KE
Bioorg Med Chem; 2011 Jun; 19(11):3416-24. PubMed ID: 21570309
[TBL] [Abstract][Full Text] [Related]
20. Rationale Design, Synthesis, Cytotoxicity Evaluation, and Molecular Docking Studies of 1,3,4-oxadiazole Analogues.
Ahsan MJ; Choupra A; Sharma RK; Jadav SS; Padmaja P; Hassan MZ; Al-Tamimi ABS; Geesi MH; Bakht MA
Anticancer Agents Med Chem; 2018; 18(1):121-138. PubMed ID: 28425854
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
